ATTR-CM is a disease in which harmful proteins build up in the heart, making it harder to pump blood, according to the ...

Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 millionGraftAssure RUO assay launched July ...

Johnson & Johnson (J&J) has received US Food and Drug Administration (FDA) approval for its interleukin 23 inhibitor, Tremfya ...

FDA stated in written correspondence for a START pilot program meeting that it is open to considering skin FXN concentration as a reasonably ...

The FDA has approved a supplemental new drug application for the treatment of cardiomyopathy wild-type or hereditary transthyretin-mediated amyloidosis.

A bill under consideration in the legislature would position Iowa to immediately allow prescriptions of a synthetic version ...

Raziel Green, 52, an active runner and mother of two, was diagnosed with a rare form of ALS in 2017. Since starting a ...

Laromestrocel (Lomecel-B™) has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for Alzheimer's disease ...

Biopharmaceutical company Rezolute, which develops treatments for a rare, congenital form ... trials. This, Verve claims, could “delay or prevent” certain drug from ever getting FDA approval.

“Receiving the FDA’s clearance to proceed with our Phase 2 clinical trial for TPST-1495 ... section of the Company’s Quarterly Report on Form 10-Q filed for the quarter ended September ...

The FDA advises 250 mg tablets to be taken thrice a day. Ctexli is the first approved drug for the condition. A 24-week clinical trial tested how well Ctexli worked in people with CTX ages 16 to ...

Received US Institutional Review Board (IRB) approval for pivotal, adaptive Phase 3 clinical trial (the "MIRACLE” trial) and ...